# Optimizing the Use of Aspirin for the Prevention of Preeclampsia

> **NCT07665853** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Hospital Universitari Vall d'Hebron Research Institute** · enrollment: 15160 (estimated)

## Conditions studied

- Preeclampsia

## Interventions

- **DRUG:** Discontinuation of Acetylsalicilic acid 150 mg/day at 24-28 weeks of gestation

## Key facts

- **NCT ID:** NCT07665853
- **Lead sponsor:** Hospital Universitari Vall d'Hebron Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2028-05
- **Final completion:** 2028-05
- **Target enrollment:** 15160 (ESTIMATED)
- **Last updated:** 2026-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07665853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07665853, "Optimizing the Use of Aspirin for the Prevention of Preeclampsia". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07665853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*